Sven Erik Godtfredsen

USPTO Granted Patents = 7 (Patent Applications = 10)

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 3 (Patent Applications = 3)

Average Co-Inventor Count = 7.1

ph-index = 2

Forward Citations = 22(Granted Patents)

Company Filing History:

Novartis Pharmaceuticals Corporation

patents

Years Active: 2014-2023

where 'Filed Patents' based on already Granted Patents

7 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11642329 - Amorphous solid form of compounds containing S—N-valeryl-N- {[2'-( 1 H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations (2023-05-09),

2. 11426375 - Substituted bisphenyl butanoic ester derivatives as NEP inhibitors (2022-08-30),

3. 11096918 - Amorphous solid form of compounds containing S—N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations (2021-08-24),

4. 10668035 - Substituted bisphenyl butanoic ester derivatives as NEP inhibitors (2020-06-02),

5. 10596151 - Methods and pharmaceutical compositions for reducing arterial stiffness with a combination of a therapeutic agent blocking the angiotensin receptor and a therapeutic agent inhibiting the NEP enzyme (2020-03-24),

6. 9388134 - Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl)-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations (2016-07-12),

7. 8877938 - Compounds containing S-N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and cations (2014-11-04),

Title: The Innovative Contributions of Sven Erik Godtfredsen

Introduction

Sven Erik Godtfredsen, an accomplished inventor based in Chatham, NJ, has made significant strides in the field of pharmaceutical innovations with a total of seven patents to his name. His expertise lies in developing advanced compounds aimed at treating various health conditions, particularly hypertension and heart failure.

Latest Patents

Among his latest innovations are several noteworthy patents that highlight his dedication to addressing critical health issues. One patent focuses on an amorphous solid form of compounds containing S—N-valeryl-N-{[2'-(1H-tetrazole-5-yl)-biphenyl-4-yl]-methyl}-valine and (2R,4S)-5-biphenyl-4-yl-4-(3-carboxy-propionylamino)-2-methyl-pentanoic acid ethyl ester moieties and sodium cations. This compound is deemed beneficial for treating hypertension and/or heart failure. Another significant patent pertains to substituted bisphenyl butanoic ester derivatives as neutral endopeptidase (NEP) inhibitors, describing a method for manufacturing these compounds and their therapeutic applications. The patent also includes pharmaceutical compositions developed from these compounds, demonstrating his impact on the pharmaceutical industry.

Career Highlights

Sven has had a distinguished career working with leading companies in the pharmaceutical sector, including Novartis AG and Novartis Pharmaceuticals Corporation. His work at these organizations has contributed to advancing drug formulations and therapies aimed at improving patient outcomes.

Collaborations

Throughout his career, Sven Erik Godtfredsen has collaborated with several notable professionals, including Yugang Liu and Mahavir Prashad. These partnerships have fostered innovative approaches and significant advancements in the field of pharmaceuticals.

Conclusion

Sven Erik Godtfredsen's contributions to pharmaceutical innovations are remarkable, with his patents reflecting a commitment to improving healthcare solutions. His work stands as a testament to the ongoing advancements in medical science and the vital role of inventors in developing life-saving treatments.

This text is generated by artificial intelligence and may not be accurate.